

**9** **Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 58399

**Manuscript Type:** META-ANALYSIS

Effectiveness of entecavir to prevent hepatocellular carcinoma development is genotype dependent in hepatitis B virus-associated liver cirrhosis

Kazuo Tarao, Akito Nozaki, Makoto Chuma, Masataka Taguri, Shin Maeda

## Match Overview

1	<b>Crossref</b> 82 words Fattovich, G.. "Natural history of chronic hepatitis B: Spec... I emphasis on disease progression and prognostic factors",	4%
2	<b>Crossref</b> 75 words "Abstracts of the 78th Annual Meeting of the Japanese Ca ncer Association; 2019 Sept 26-28; Kyoto, Japan" as Car...	3%
3	<b>Crossref</b> 54 words Li Zhang, Fu-Kui Zhang. "Recent advances in assessmer... and treatment of chronic hepatitis B", <i>World Chinese Journ</i>	2%
4	<b>Crossref</b> 14 words Honda, Koichi. "Benefits of nucleos(t)ide analog treatmer ... for hepatitis B virus-related cirrhosis", <i>World Journal of Hep</i>	1%
5	<b>Internet</b> 14 words crawled on 05-Jun-2019 <a href="http://aasldpubs.onlinelibrary.wiley.com">aasldpubs.onlinelibrary.wiley.com</a>	1%
6	<b>Crossref</b> 13 words "Abstracts—APASL 2013", <i>Hepatology International</i> , 2013	1%



ALL

IMAGES

VIDEOS

57,700 Results

Any time ▾

## Prevention of hepatocellular carcinoma in patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133443>

Aug 06, 2014 · As cirrhosis is in itself a risk factor for **HCC development**[1,5], the reversal of **cirrhosis** associated with long-term **HBV viral** suppression by **effective** antiviral therapy may, at least in part, decrease the risk for **HCC development**. Patients treated with **entecavir** in two phase 3 studies in nucleoside-naïve patients with HBeAg-positive and HBeAg-negative disease, respectively, and who ...

Cited by: 12

Author: Conrado M Fernández-Rodríguez, María Lui...

Publish Year: 2014

## Current perspectives into the evaluation and management of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700007>

Liver cancer and HBV. HBV is the most common cause of **HCC**, being responsible for >50% of cases worldwide ().The relative risk of developing **HCC** increases by 15–20-fold in patients with HBV compared to uninfected patients with an annual incidence of **HCC** in hepatitis B carriers of 0.5% (19,20).It is thought that 10–16% of patients with **HCC** in the US are infected with HBV ().

Cited by: 1

Author: Vignan Manne, Eric Gochanour, Kris V. Kow...

Publish Year: 2019

## Antiviral treatment to prevent chronic hepatitis B or C

## Search Tools

Turn on Hover Translation (开启取词)

Effectiveness of entecavir to prevent hepatocellular carcinoma devel



ALL

IMAGES

VIDEOS

63,000 Results

Any time ▾

## [Long-term entecavir treatment reduces hepatocellular ...](#)

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26180>

Jing Sun, Yanfang Li, Yanna Wang, Yanyan Liu, Youde Liu, Xiumei Wang, Comparison of anti-HBV regimen with or without adefovir on **hepatocellular carcinoma development** of Chronic **hepatitis B** patients with compensated **cirrhosis**: a retrospective cohort study, *Infectious Agents and Cancer*, 10.1186/s13027-018-0189-2, 13, 1, (2018).

**Cited by:** 650

**Author:** Tetsuya Hosaka, Fumitaka Suzuki, Masa...

**Publish Year:** 2013

## [Antiviral treatment to prevent chronic hepatitis B or C ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782279>

Dec 12, 2012 · INTRODUCTION. **Hepatocellular carcinoma** (HCC), one of the most common and aggressive malignancies, is the third leading cause of cancer-related deaths worldwide[]. Chronic infection with **hepatitis B** virus (HBV) and **hepatitis C** virus (HCV) affect over 400 million and 170 million individuals respectively, together contributing to 75%-80% of global HCC[].

**Cited by:** 19

**Author:** Li-Ping Chen, Jun Zhao, Yan Du, Yi-Fang...

**Publish Year:** 2012



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

61,700 Results Any time ▾

### Long-term entecavir treatment reduces hepatocellular ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26180>

Jing Sun, Yanfang Li, Yanna Wang, Yanyan Liu, Youde Liu, Xiumei Wang, Comparison of anti-HBV regimen with or without adefovir on **hepatocellular carcinoma development** of Chronic **hepatitis B** patients with...

**Cited by:** 650 **Author:** Tetsuya Hosaka, Fumitaka Suzuki, Masahir...

**Publish Year:** 2013

### Entecavir for the treatment of real-life chronic hepatitis ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078629>

Approximately 400 million people are chronically infected with **hepatitis B** virus (HBV). 1 When they are left untreated, the disease progresses to **cirrhosis** and **hepatocellular carcinoma**. 2, 3 Saudi Arabia is...

**Cited by:** 2 **Author:** Hamad Ibrahim Al-Ashqar, Mohamméd Al-...

**Publish Year:** 2013

### Antiviral treatment to prevent chronic hepatitis B or C ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782279>

Dec 12, 2012 · INTRODUCTION. **Hepatocellular carcinoma** (HCC), one of the most common and aggressive malignancies, is the third leading cause of cancer-related deaths worldwide].Chronic infecti...

**Cited by:** 19 **Author:** Li-Ping Chen, Jun Zhao, Yan Du, Yi-Fang Ha...

**Publish Year:** 2012

### Effects of long-term entecavir treatment on the incidence ...

<https://www.researchgate.net/publication/280392803...>

The **hepatitis B** virus (HBV), discovered in 1966, infects more than 350 million people worldwide.1

**Hepatitis B** is a leading cause of chronic **hepatitis**, **cirrhosis**, and **hepatocellular carcinoma** ...

### Predictive Value of Antiviral Effects in the Development ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087937>

INTRODUCTION. Chronic **hepatitis B** virus (HBV) infection is the primary cause of **hepatocellular carcinoma** (HCC), accounting for approximately 75% of its underlying etiologies in Korea. 1 Although the...